European Commission Approves Erbitux for First-Line Use in Head and Neck Cancer
December 1, 2008 by Marijke Durning, RN
Filed under Diseases & Conditions
The European Commission has approved the use of Erbitux (cetuximab), previously approved for use in combination with radiotherapy, as a first-line treatment of head and neck cancer.
Erbutix was the subject of the EXTREME study, which was published in the the New England Journal of Medicine a few months ago. The researchers had found that there was a medial overall survival rate increase of almost three months among patients who took Erbutix.
To read more about Erbutix and its effect on head and neck cancer, you can go to the article, European Commission Approves Erbitux for First-Line Use in Head and Neck Cancer.
~~~
Tags: cancer blog, head and neck cancer, erbutix, erbutix approval, erbutix european approval, ceftuximab
